You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Details for Patent: 9,493,582

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,493,582 protect, and when does it expire?

Patent 9,493,582 protects BAXDELA, EVOMELA, KYPROLIS, CARNEXIV, NOXAFIL, and SESQUIENT, and is included in six NDAs.

This patent has twenty-two patent family members in ten countries.

Summary for Patent: 9,493,582

Title:	Alkylated cyclodextrin compositions and processes for preparing and using the same
Abstract:	The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.
Inventor(s):	Antle; Vincent D. (Olathe, KS), Lopes; Alvaro (Loures, PT), Monteiro; Daniel (Loures, PT)
Assignee:	Cydex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	14/381,568
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,493,582
Patent Claim Types: see list of patent claims	Use; Composition; Process; Formulation;

Drugs Protected by US Patent 9,493,582

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-003	Jun 7, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,493,582

PCT Information
PCT Filed	February 27, 2013	PCT Application Number:	PCT/US2013/028094
PCT Publication Date:	September 06, 2013	PCT Publication Number:	WO2013/130666

International Family Members for US Patent 9,493,582

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013226073	⤷ Sign Up
Australia	2016210707	⤷ Sign Up
Canada	2865950	⤷ Sign Up
China	104704007	⤷ Sign Up
China	110066351	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.